Erschienen in:
01.05.2023 | Brief Report
Synthetic dibenzylideneketones as promising anti-herpes simplex virus type 1 agents
verfasst von:
Thalita Zago Oliveira, Dyenefer Pereira Fonseca, André Henrique dos Santos, Thays Rosa da Silva, Danielle Lazarin-Bidóia, Zia Ud Din, Benedito Prado Dias Filho, Celso Vataru Nakamura, Edson Rodrigues-Filho, Tania Ueda-Nakamura
Erschienen in:
Archives of Virology
|
Ausgabe 5/2023
Einloggen, um Zugang zu erhalten
Abstract
New antiviral agents for the treatment of herpes simplex virus type 1 (HSV-1) infection, which causes a highly prevalent and incurable disease, are needed. Here, we report for the first time the in vitro anti-HSV-1 activity of two dibenzylideneketone compounds: DBK1 and DBK2. DBK1 demonstrated virucidal activity, and high-resolution scanning electron microscopy showed that it caused morphological changes in the HSV-1 envelope. DBK2 was able to reduce HSV-1 plaque size in vitro. The DBKs are promising anti-HSV-1 candidates, as they exhibit low toxicity and exert an antiviral effect by acting at the early stages of HSV-1-host cell interaction.